{"pub": "investingcom", "url": "https://in.investing.com/news/stock-market-news/briefaridis-pharmaceuticals-says-license-agreement-with-the-serum-institute-of-india-1995809", "downloaded_at": "2019-09-30 10:47:21.586845+00:00", "title": "BRIEF-Aridis Pharmaceuticals Says License Agreement With The Serum Institute Of India", "language": "en", "text": "BRIEF-Aridis Pharmaceuticals Says License Agreement With The Serum Institute Of India\n\nStock Markets 27 minutes ago (Sep 30, 2019 15:50)\n\n\u00a9 Reuters. BRIEF-Aridis Pharmaceuticals Says License Agreement With The Serum Institute Of India Sept 30 (Reuters) - Aridis Pharmaceuticals Inc : * ARIDIS PHARMACEUTICALS EXECUTES LICENSE AGREEMENT WITH THE SERUM INSTITUTE OF INDIA, LTD. FOR EXCLUSIVE RIGHTS TO PRODUCTS AND UTILIZATION OF MABIGX\u00ae PLATFORM TECHNOLOGY * ARIDIS PHARMACEUTICALS - UNDER DEAL, CO TO RECEIVE REMAINING UPFRONT CASH PAYMENT OF $10 MILLION, IN ADDITION TO $5 MILLION THAT WAS INITIALLY RECEIVED\n\nBRIEF-Aridis Pharmaceuticals Says License Agreement With The Serum Institute Of India", "description": "BRIEF-Aridis Pharmaceuticals Says License Agreement With The Serum Institute Of India", "authors": [], "top_image": "https://i-invdn-com.akamaized.net/news/LYNXMPEB2C0AG_L.jpg", "published_at": "2019-09-30"}